Roivant Sciences Ltd. (ROIV) Stock
ROIV Key Statistics
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
CEO: Matthew Gline. Company website
ROIV — Frequently Asked Questions
What is the ROIV stock price today?
Roivant Sciences Ltd. (ROIV) trades at $41.85, up 1.60% on the day, as of Nov 12, 2026 09:30 UTC.
What is Roivant Sciences Ltd.'s market cap?
Roivant Sciences Ltd. has a market capitalisation of $30.23B, calculated from the live ROIV share price and shares outstanding.
What is the P/E ratio of ROIV?
ROIV has no meaningful price-to-earnings ratio: Roivant Sciences Ltd. lost $0.49 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Roivant Sciences Ltd. make?
Roivant Sciences Ltd. generated revenue of $41.08M over the trailing twelve months, which puts the stock at 735.83 times sales.
What is the 52-week range for ROIV?
ROIV has traded between $19.79 and $42.50 over the past 52 weeks, and the last price is 1.5% below that high.
Is Roivant Sciences Ltd. profitable?
No. Roivant Sciences Ltd. is loss-making, with a net margin of -838.21% over the trailing twelve months.
What is the analyst price target for ROIV?
Wall Street analysts rate ROIV Buy, with an average price target of $47.71, 14.0% above the current price.
What sector is Roivant Sciences Ltd. in?
Roivant Sciences Ltd. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in GB.
Who is the CEO of Roivant Sciences Ltd.?
Matthew Gline is the chief executive of Roivant Sciences Ltd., which employs 721 people.
Where can I track ROIV in real time?
QFI Terminal shows ROIV with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ROIV live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ROIV in Terminal See plans